Sign up
Pharma Capital

Lannett Company gets FDA nod for generic flu drug

"We expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.
flu patient
Its the first product to clear FDA approval after pharmacokinetic by DarmanTest

Generic drug manufacturer Lannett Company Inc (NYSE: LCI) is looking forward to the next flu season after securing approval for a new product, comparable to the Symmetrel branded treatment.

The Food and Drug Administration (FDA) has signed off Lannett’s Amantadine Hydrochloride Capsules, described as being the ‘therapeutic equivalent’ of the reference standard drug which is produced by Sandoz Pharmaceuticals.

"While this approval comes too late to benefit fiscal 2017, which ends later this month, we expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.

He also highlighted that the approval was approved in 15 months, and it represents the first product to be approved following bio-equivalency study at the company’s pharmacokinetic subsidiary, DarmanTest Laboratories.  

Jamie_55a91591db06b.jpg


Register here to be notified of future LCI Company articles
View full LCI profile

Lannett Company Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.